Suppr超能文献

加兰他敏用于治疗可能患有或未患有脑血管疾病的泰国阿尔茨海默病患者的行为和心理症状。

Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.

作者信息

Tangwongchai S, Thavichachart N, Senanarong V, Poungvarin N, Phanthumchinda K, Praditsuwan R, Nidhinandana S, Chankrachang S

机构信息

Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Am J Alzheimers Dis Other Demen. 2008;23(6):593-601. doi: 10.1177/1533317508320603. Epub 2008 Oct 9.

DOI:10.1177/1533317508320603
PMID:18845693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10846018/
Abstract

OBJECTIVES

This study was to investigate an efficacy of galantamine in treatment of behavioral and psychological symptoms of dementia in Thai elderly who suffered from possible Alzheimer's disease (AD) with or without cerebrovascular disease and vascular dementia.

METHODS

A 6-month, multicenter, open-label, uncontrolled trial was undertaken in 75 patients. Eligible patients received an initial galantamine dose of 8 mg/dayand escalated over 5 to 8 weeks to maintenance doses of 16 or 24 mg/day. The behavioral response was assessed as an intention-to-treat analysis using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).

RESULTS

Galantamine improved behavioral and psychological symptoms of dementia (P < .05 vs baseline) over the 24 weeks of treatment. BEHAVE-AD score was significantly improved from baseline in paranoid and delusion ideation, diurnal rhythm disturbances, anxieties, and phobias.

CONCLUSIONS

Galantamine may be a well-tolerated and effective treatment option for improving psychotic, behavioral, and psychological symptoms in Thai elderly with possible AD with or without cerebrovascular disease and vascular dementia.

摘要

目的

本研究旨在调查加兰他敏对患有可能的阿尔茨海默病（AD）且伴有或不伴有脑血管疾病及血管性痴呆的泰国老年痴呆患者行为和心理症状的治疗效果。

方法

对75例患者进行了一项为期6个月的多中心、开放标签、非对照试验。符合条件的患者初始加兰他敏剂量为8毫克/天，并在5至8周内逐渐增加至16或24毫克/天的维持剂量。使用阿尔茨海默病行为病理评定量表（BEHAVE-AD）对行为反应进行意向性分析评估。

结果

在24周的治疗期间，加兰他敏改善了痴呆的行为和心理症状（与基线相比，P < 0.05）。BEHAVE-AD评分在偏执和妄想观念、昼夜节律紊乱、焦虑和恐惧症方面较基线有显著改善。

结论

对于患有可能的AD且伴有或不伴有脑血管疾病及血管性痴呆的泰国老年患者，加兰他敏可能是一种耐受性良好且有效的治疗选择，可改善其精神病性、行为和心理症状。

相似文献

1
Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
Am J Alzheimers Dis Other Demen. 2008;23(6):593-601. doi: 10.1177/1533317508320603. Epub 2008 Oct 9.
2
Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
CNS Drugs. 2003;17(12):905-14. doi: 10.2165/00023210-200317120-00004.
3
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
Int J Clin Pract. 2006 May;60(5):533-40. doi: 10.1111/j.1368-5031.2006.00892.x.
4
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
Eur J Neurol. 2003 Nov;10(6):633-40. doi: 10.1046/j.1468-1331.2003.00677.x.
5
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
J Alzheimers Dis. 2014;39(3):477-85. doi: 10.3233/JAD-131190.
6
An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Clin Ther. 2003 Jun;25(6):1765-82. doi: 10.1016/s0149-2918(03)80168-6.
7
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Lancet. 2002 Apr 13;359(9314):1283-90. doi: 10.1016/S0140-6736(02)08267-3.
8
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Curr Neurol Neurosci Rep. 2002 Sep;2(5):389-90. doi: 10.1007/s11910-002-0062-x.
9
[Use of reminyl (galantamine) in the treatment of dementia].
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(3):26-30.
10
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
Curr Neurol Neurosci Rep. 2002 Nov;2(6):503-4. doi: 10.1007/s11910-002-0036-z.

引用本文的文献

1
The Relationship Between Antipsychotics, Cognitive Enhancers, and Major Adverse Cardiovascular/Cerebrovascular Events (MACCE) in Older Adults with Behavioral and Psychological Symptoms of Dementia.
Drugs Aging. 2024 Oct;41(10):847-858. doi: 10.1007/s40266-024-01134-9. Epub 2024 Aug 9.
2
Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer's Disease, Vascular Dementia, or Mixed Dementia.
Geriatrics (Basel). 2017 Aug 27;2(3):29. doi: 10.3390/geriatrics2030029.
3
The role of phytochemicals in the treatment and prevention of dementia.
Drugs Aging. 2011 Jun 1;28(6):439-68. doi: 10.2165/11591310-000000000-00000.
4
Behavioral and psychological symptoms of dementia and their management.
Indian J Psychiatry. 2009 Jan;51 Suppl 1(Suppl1):S77-86.

本文引用的文献

1
Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.
Am J Psychiatry. 2007 Oct;164(10):1568-76; quiz 1623. doi: 10.1176/appi.ajp.2007.06101710.
2
A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Int J Clin Pract. 2007 Mar;61(3):403-10. doi: 10.1111/j.1742-1241.2007.01284.x.
3
Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Drugs Aging. 2006;23(6):503-11. doi: 10.2165/00002512-200623060-00005.
4
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
Int J Clin Pract. 2006 May;60(5):533-40. doi: 10.1111/j.1368-5031.2006.00892.x.
5
Cholinesterase inhibitors for Alzheimer's disease.
Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593.
6
Galantamine for Alzheimer's disease and mild cognitive impairment.
Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD001747. doi: 10.1002/14651858.CD001747.pub3.
7
Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.
Dement Geriatr Cogn Disord. 2006;21(2):120-9. doi: 10.1159/000090630. Epub 2006 Jan 2.
8
Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
N Engl J Med. 2005 Dec 1;353(22):2335-41. doi: 10.1056/NEJMoa052827.
9
Relationship between delusions and regional cerebral blood flow in Alzheimer's disease.
Dement Geriatr Cogn Disord. 2006;21(1):16-21. doi: 10.1159/000089215. Epub 2005 Oct 25.
10
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
JAMA. 2005 Oct 19;294(15):1934-43. doi: 10.1001/jama.294.15.1934.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验